Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
Dementia01:30

Dementia

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Cognitive Development During Adulthood01:30

Cognitive Development During Adulthood

Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Intellectual Disability01:29

Intellectual Disability

Intellectual disability (ID) is a neurodevelopmental condition characterized by deficits in intellectual and adaptive functioning that manifest during the developmental period. This condition encompasses challenges in reasoning, memory, problem-solving, and learning, accompanied by impairments in everyday life skills, such as communication, self-care, and social interactions. Intellectual disability affects approximately 1% of the population in the United States, impacting an estimated 5...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Response to "Reanalyzing the impact of cognitive training over 20 years in the ACTIVE study: Losing the forest in the trees".

Alzheimer's & dementia (New York, N. Y.)·2026
Same author

Phenotyping antidepressant treatment response with deep learning in electronic health records.

Translational psychiatry·2026
Same author

Can the All of Us sample be reweighted to mirror a nationally representative sample? A comparison of mortality predictors.

Epidemiology (Cambridge, Mass.)·2026
Same author

Development and validation of a harmonized memory score for multicenter Alzheimer's disease and related dementia research.

Alzheimer's research & therapy·2026
Same author

Improvements in Cogstate Test Performance Depend on Number and Frequency of Prior Tests: Evidence from a Randomized Follow-Up Design.

Alzheimer disease and associated disorders·2026
Same author

Post-Discharge Anti-Seizure Medication Use Improves Post-Stroke Survival: <i>An Emulated Target Trial in Older Adults</i>.

medRxiv : the preprint server for health sciences·2026

Related Experiment Video

Updated: Jul 12, 2026

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
12:18

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment

Published on: January 11, 2020

Mild cognitive impairment and dementia.

Marilyn S Albert1, Deborah Blacker

  • 1Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21212, USA. malbert9@jhmi.edu

Annual Review of Clinical Psychology
|August 25, 2007
PubMed
Summary

Mild cognitive impairment (MCI) signifies a stage between normal cognition and dementia. Understanding MCI

Area of Science:

  • Neurology
  • Gerontology
  • Neuroscience

Background:

  • Mild cognitive impairment (MCI) is recognized as a transitional phase between normal aging and dementia.
  • The concept of MCI has evolved due to its inherent heterogeneity.
  • This heterogeneity impacts the design and outcomes of clinical trials for MCI.

Purpose of the Study:

  • To review evidence supporting MCI as a distinct transitional stage.
  • To explore the heterogeneity of MCI and its influence on the evolving definition.
  • To discuss the implications of MCI heterogeneity for clinical trial outcomes.

Main Methods:

  • Literature review of studies on MCI.
  • Analysis of data supporting the transitional nature of MCI.
  • Examination of how MCI heterogeneity affects clinical trial designs and results.

More Related Videos

The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease
06:23

The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease

Published on: October 13, 2016

Dual-Task Stroop Paradigm for Detecting Cognitive Deficits in High-Functioning Stroke Patients
07:42

Dual-Task Stroop Paradigm for Detecting Cognitive Deficits in High-Functioning Stroke Patients

Published on: December 16, 2022

Related Experiment Videos

Last Updated: Jul 12, 2026

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
12:18

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment

Published on: January 11, 2020

The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease
06:23

The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease

Published on: October 13, 2016

Dual-Task Stroop Paradigm for Detecting Cognitive Deficits in High-Functioning Stroke Patients
07:42

Dual-Task Stroop Paradigm for Detecting Cognitive Deficits in High-Functioning Stroke Patients

Published on: December 16, 2022

Main Results:

  • Evidence supports MCI as a transitional phase from normal function to dementia.
  • MCI is a heterogeneous condition, impacting its definition and study.
  • Heterogeneity in MCI poses challenges for clinical trials.

Conclusions:

  • MCI represents a critical transitional phase in cognitive decline.
  • Acknowledging MCI heterogeneity is crucial for accurate diagnosis and research.
  • Future MCI research and trials must account for this heterogeneity.